Replies to post #100203 on Biotech Values

[iwfal]

SVR was negligible also .

Agreed. But my specific point was that the relapse time constant was shorter under ifn monotherapy - making the larger point that the time constant might well be different with the introduction of DAAs.

Maybe with the orals the 12 wk EOT will be a valid time frame but i have not seen any conclusive data. Have you ?

Most definitely not. And I agree with Dew when he says that it is misleading to quote SVR12 - at least until there is relapse time constant data for DAA regimens.

And note that the data from this trial might provide some insight into that time constant if they report both SVR12 and later SVR24.

PS What this means is that even when SVR24 rates are reported for DAA + SOC I am a little sceptical until I see data about relapse time constant. Not that I totally discount SVR24 data for such regimens - but I reserve a little doubt.